| Date | Time | Source | |
| 05/22/2013 | 5:50PM | ZACKS | XenoPort Resumes Horizant Supply - Analyst Blog
XenoPort Inc. (XNPT) recently commenced shipments of Horizant extended-release tablets in the US. The drug is approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as for the management of postherpetic neuralgia (PHN) in adults. XenoPort mentioned in its press release that... More...>> |
| 05/21/2013 | 6:10PM | ZACKS | XenoPort Candidate Disappoints - Analyst Blog
XenoPort, Inc. (XNPT) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228). Results from the phase III trial showed that AP failed to achieve statistically significant improvement compared to placebo in patients suffering from spasticity due to multiple sclerosis... More...>> |
| 05/20/2013 | 9:29AM | DJN | U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Among the companies with shares expected to actively trade in Monday's session are Websense Inc. (WBSN), Acquity Group Ltd. (AQ) and JA Solar Holdings Co. (JASO). Websense has agreed to be acquired by Vista Equity Partners. Websense stockholders will receive $24.75 in cash for each share of Websense common stock, a 29... More...>> |
| 05/20/2013 | 6:30AM | BW | XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
XenoPort, Inc. (Nasdaq: XNPT) announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the treatment of patients with spasticity due to multiple sclerosis (MS). The trial was unsuccessful in demonstrating that AP provided statistically significant improvement relative to... More...>> |
| 05/17/2013 | 8:30AM | BW | XenoPort Provides Update on Availability of Horizant
XenoPort, Inc. (Nasdaq: XNPT) announced today that shipments of Horizant® (gabapentin enacarbil) Extended-Release Tablets to its distributor in the United States have commenced. Depending on individual pharmacy ordering patterns, the product is anticipated to be generally available to patients in the first week of June... More...>> |
| 05/03/2013 | 4:30PM | BW | XenoPort Announces New Employment Inducement Awards
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to two new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employees were granted stock options to purchase an aggregate of 36,500 shares of XenoPort's common stock and restricted stock units representing... More...>> |
| 04/25/2013 | 8:18AM | ZACKS | Loss Widens at XenoPort - Analyst Blog
XenoPort, Inc. (XNPT) reported first quarter 2013 loss of 50 cents per share, wider than the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 26 cents per share. Quarterly revenues were $0.5 million as against $10.4 million in the year-ago period. Revenue in the reported quarter was also below the... More...>> |
| 04/24/2013 | 4:05PM | BW | XenoPort Reports First Quarter Financial Results
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the first quarter ended March 31, 2013. Revenues for the quarter were $0.5 million, compared to $10.4 million for the same period in 2012. Net loss for the first quarter was $23.5 million, compared to a net loss of $9.1 million for the same period... More...>> |
| 04/22/2013 | 7:25AM | ZACKS | Bearish MACD for XenoPort, Inc. - Tale of the Tape
XenoPort, Inc.’s (XNPT) MACD indicator has moved into bearish territory with a reading of –0.0803. The Zacks Rank #4 (“Sell”) stock decreased more than 5.17% to $7.15 in morning trade. The Zacks Consensus Estimate on the company’s loss for the year ending December 2013 has increased by 30... More...>> |
| 04/17/2013 | 6:14PM | BW | XenoPort to Release First Quarter Financial Results on April 24
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on April 24, 2013 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. To access... More...>> |
| 04/12/2013 | 7:29AM | DJN | XenoPort: Manufacturing Delays Caused Stockout of Horizant
By Ben Fox Rubin Biopharmaceutical firm XenoPort Inc. (XNPT) said GlaxoSmithKline PLC (GSK, GSK.LN) has experienced manufacturing delays that resulted in stockout of Horizant, a restless-leg syndrome drug. Glaxo holds commercialization rights to the drug in the U.S. during a transition period that ends April 30. The company... More...>> |
| 04/12/2013 | 6:30AM | BW | XenoPort Provides Update on Its Introduction of Horizant
XenoPort, Inc. (Nasdaq: XNPT) reported today that GlaxoSmithKline (GSK), who holds commercialization rights to Horizant® (gabapentin enacarbil) Extended-Release Tablets in the United States during a transition period ending on April 30, 2013, has experienced manufacturing delays that have resulted in a stockout of Horizant... More...>> |
| 04/05/2013 | 4:30PM | BW | XenoPort Announces New Employment Inducement Awards
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to eight new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employees were granted stock options to purchase an aggregate of 52,500 shares of XenoPort's common stock and restricted stock units representing... More...>> |
| 03/28/2013 | 6:59AM | ZACKS | Bearish MACD for XenoPort, Inc. - Tale of the Tape
XenoPort, Inc.’s (XNPT) MACD indicator has moved into bearish territory with a reading of –0.2642. The Zacks Rank #4 (“Sell”) stock decreased more than 1.54% to $7.12 in morning trade. The Zacks Consensus Estimate on the company’s loss for the year ending December 2013 has increased by 34... More...>> |
| 03/18/2013 | 8:30AM | BW | XenoPort Announces Presentations at the American Academy of Neurology Meeting
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present the following posters at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California: AP (arbaclofen placarbil)Spasticity An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil... More...>> |
| 03/15/2013 | 11:25AM | ZACKS | 4Q Loss Narrows at Xenoport - Analyst Blog
Xenoport, Inc. (XNPT) reported fourth quarter 2012 loss of 38 cents per share, narrower than the Zacks Consensus Estimate of a loss of 42 cents per share and the year-ago loss of 56 cents per share. Quarterly revenues were $0.5 million as against $5.4 million in the year-ago period, narrower than the Zacks Consensus Estimate... More...>> |
| 03/11/2013 | 4:05PM | BW | XenoPort Reports Fourth Quarter and Year-End 2012 Financial Results
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2012. Revenues for the quarter were $0.5 million, compared to $5.4 million for the same period in 2011. Net income for the fourth quarter was $3.0 million, which resulted from a non-cash gain on XenoPort’s... More...>> |
| 03/04/2013 | 7:27PM | BW | XenoPort to Release Fourth Quarter and Year-End Financial Results on March 11, 2013
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its fourth quarter financial results on March 11, 2013 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. To... More...>> |
| 03/04/2013 | 5:59PM | BW | XenoPort Announces New Employment Inducement Awards
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to three new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employees were granted stock options to purchase an aggregate of 8,000 shares of XenoPort's common stock and restricted stock units representing... More...>> |
| 03/01/2013 | 12:46PM | BW | XenoPort to Present at the Cowen and Company 33rd Annual Health Care Conference
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Cowen and Company 33rd Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 6, 2013. A replay of the presentation... More...>> |
